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Background: The role of M2 polarized macrophages (MΦ) during the allergic airway inflammation has been
discussed in various animal models. However, their presence and relevance during the chronic and acute phase of
allergic airway inflammation in humans has not been fully elucidated so far. In the present study we phenotypically
characterized macrophages with regard to M2 polarization in mice, a human in vitro and a human ex vivo model
with primary lung cells after endobronchial provocation.
Results: Macrophages remained polarized beyond clearance of the acute allergic airway inflammation in mice.
Alveolar macrophages of asthmatics revealed increased mRNA expression of CCL13, CCL17 and CLEC10A in
response to allergen challenge as well as increased surface expression of CD86. Further, mRNA expression of CCL13,
CCL17, and CLEC10A was increased in asthmatics at baseline compared to healthy subjects. The mRNA expression
of CCL17 and CLEC10A correlated significantly with the degree of eosinophilia (each P < .01). Furthermore,
macrophages from asthmatics released significant amounts of CCL17 protein in vitro which was also found
increased in BAL fluid after allergen provocation.
Conclusions: This study supports previous findings of M2 macrophage polarization in asthmatic subjects during
the acute course of the allergic inflammation and provides evidence for their contribution to the Th2 inflammation.
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Pulmonary dendritic cells, activated Th2 effector cells,
and their respective cytokine and chemokine networks
in the sensitization and initiation phase of allergic airway
inflammation have been explored intensively [1-3]. The
question, whether the most abundant resident cell type
in the alveolar space, the macrophage, plays a significant
role in these processes has been neglected in this setting
for years [4]. Increasing knowledge about macrophage
polarization brought alveolar macrophages back into
focus. In the context of allergic airway inflammation the
contribution of the alternatively activated M2 phenotype
with its specific functionality appears to be of special
interest [5].* Correspondence: jens.hohlfeld@item.fraunhofer.de
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reproduction in any medium, provided the orM2 polarization encompasses at least two subtypes
M2 and M2-like macrophages dependent on the cytokine
milieu macrophages are subjected to. M2 macrophages
differentiate in response to IL-4 and IL-13 whereas M2-
like macrophages acquire their phenotype in response to
TGF-b, IL-10 or PGE and additional TLR activation [6].
M2-like macrophages release high amounts of IL-10 and
are thus considered to be anti-inflammatory. However,
M2 macrophages are functionally considered to promote
clearance of parasite infections [7], they are involved in
tumor progression [8], and they contribute to tissue re-
modeling [9]. Markers for M2 macrophages differ between
mice and man, with Ym1, Fizz1, Arg specifically described
to be up-regulated in mice [10], whereas expression of the
mannose receptor CD206 was defined for M2 macro-
phages from both species [11,12]. In humans, several
markers for M2 polarization have been described such as
up-regulation of HLA-DR and increased expression of
Th2 chemokines CCL17, CCL18, CCL22 and CCL24 [13].
Importantly, most data on macrophage polarization areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and man are not identical, and our understanding of the
characteristics of M2 polarization in human asthma is still
incomplete [14]. Recently, Staples and colleagues pub-
lished an important paper in which they phenotypically
characterized M2 polarization of alveolar macrophages in
a group of non-asthmatic subjects and asthmatic patients
[15]. Using the currently accepted panel of human M2
markers, they showed a partial M2 polarization of sputum
and BAL macrophages in symptom-free asthmatics.
Interestingly, the CCR4 ligand CCL17, a key chemokine
for the recruitment of CCR4+ effector cells, was promin-
ently induced, indicating that M2 macrophages might also
facilitate the inflammatory immune response in humans.
With the current study we extended the phenotypic
and functional characterization of alveolar macrophages
in asthmatic patients, by paying special attention to the
late phase of allergic airway inflammation. Therefore,
we investigated macrophage polarization before and
after endobronchial allergen challenge. As significant
levels of IL-4 and IL-13 are predominantly present in
the acute effector phase of the allergen response, we
first assessed the kinetics of macrophage polarization in
a murine asthma model beyond the acute phase of
inflammation. To study M2 polarization, we further estab-
lished a human in vitro model with monocyte-derived
macrophages (MDM) of atopic donors. Subsequently, hu-
man alveolar macrophages isolated from non-asthmaticFigure 1 Kinetics of M2 polarization in mice after the induction of an
and interstitial (IMΦ, closed circles) macrophages were isolated 1 day (24 h
A, Eosinophil numbers, IL-4 and IL-13 levels (n = 7). Data were analyzed wit
Arginase, Fizz1, and YM1 are presented as fold induction compared to PBSand mild asthmatic subjects undergoing an endobronchial
allergen challenge were analyzed. Two doses of allergen
were used in separate lobes of the subjects in order to
investigate the impact of the severity of the inflammatory
response on the extent of polarization. Our findings con-
firm and extend previous findings and provide data about
the plasticity of macrophages in mild asthmatic subjects
under stable non-inflamed conditions and during the late
phase of the allergic airway inflammation.
Results
M2 polarization persists after resolution of the acute
allergic airway inflammation in mice
To evaluate the time course of alternative activation of
pulmonary macrophages a mouse model of acute allergic
airway inflammation was used to study the expression of
M2 marker genes in alveolar and interstitial lung macro-
phages. The mRNA expression of previously described
murine M2 markers (Arg, Fizz1 and Ym1) and iNOS (M1
marker) was analyzed over a period of three weeks after
the induction of acute inflammation in mice. The inflam-
mation kinetic assessed by inflammatory cell influx and
cytokine levels in BAL revealed elevated eosinophils 24 h
and 1 week after allergen provocation (P < .001), whereas
IL-4 and IL-13 levels in BAL were only increased during
the peak of the acute inflammation at 24 h (P < .001)
(Figure 1, A). Messenger RNA expression of Arg, Fizz1,
and Ym1 was markedly increased in alveolar and interstitialacute allergic airway inflammation. Alveolar (AMΦ, open circles)
), 1 week (wk), 2 wk and 3 wk after ovalbumin aerosol provocation.
h one way ANOVA. *** P < .001. B, Gene expression of M2 markers
treated mice (each data point represents n = 5 pooled animals).
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to the control group (Figure 1, B) whereas iNOS mRNA
expression was not altered (data not shown). The ex-
pression of M2 marker genes declined over time, but
after three weeks AMΦ still revealed a higher expres-
sion of these genes compared to the control group.
Interestingly, the level of expression for the 3 genes in
IMΦ and AMΦ constantly fell to 3.3 ± 0.3% at 3 weeks
compared to 24 h.In vitro M2 polarization of human derived macrophages
To characterize M2 markers in human cells in more de-
tail, macrophages were generated from peripheral blood
monocytes of atopic subjects and stimulated with IL-4 ±
allergen. Co-stimulatory surface markers like HLA-DR
and CD86 were significantly up-regulated on the surface
of macrophages in the presence of IL-4 (P < .01) compared
to control macrophages (Figure 2, A). Protein expression
of the mannose receptor (CD206) was not regulated by
IL-4 (data not shown). Compared to control macrophages,
the mRNA expression of M2 markers CCL13, CCL17,
CCL18 (data not shown), CCL23 as well as CLEC10A
were found to be significantly increased in the presence
of IL-4 (all P < .01) (Figure 2, B). Interestingly, the mRNA
expression of CCL17 was further increased when allergen
was present during stimulation with IL-4 (P < .01), whereasFigure 2 Characterization of human monocyte-derived macrophages
allergen. A, Surface marker expression of HLA-DR and CD86 measured by
(MFI). B, mRNA expression of M2 markers measured by RT-PCR as fold indu
data were analyzed with one way ANOVA (n = 5). **P < .01, and *** P < .001allergen exposure during culture had no effect on the
mRNA expression of other M2 markers.
Induction of autologous lymphocyte proliferation by
human MDM
As mouse M2 macrophages revealed an increase of co-
stimulatory molecules and an enhanced endocytosis of
soluble antigens [11], we investigated the potential of these
macrophages to present antigen to autologous T-cells. Mac-
rophages were generated from human peripheral mono-
cytes isolated from asthmatic patients and stimulated with
IL-4 and in addition with grass allergen extract prior to
co-culture with autologous lymphocytes.
Native macrophages, not stimulated with IL-4, did not
induce any T-cell proliferation in contrast to M2 (IL-4
stimulated) macrophages which induced low but signifi-
cant induction of proliferation when primed with allergen
(P < .01) (Figure 3, A). In comparison to professional anti-
gen presenting dendritic cells (generated in the same
model), M2 macrophages revealed a five-fold lower
capacity to induce specific T-cell proliferation (data
not shown).
Analysis of cytokines in the supernatant after IL-4 stimu-
lation revealed increased amounts of CCL17 compared to
control MΦ. Furthermore, macrophages induced Th2
cytokine release like IL-2, IL-10 and IL-13 by lymphocytes
when stimulated with IL-4 and allergen (Figure 3, B). Inwhich were alternatively activated in the presence of IL-4 and
flow cytometry after 48 h of polarization as mean fluorescence intensity
ction compared with control macrophages. Bars indicate mean values;
.
Figure 3 Characterization of autologous lymphocyte proliferation by in vitro IL-4 polarized human monocyte-derived macrophages
(MDM). A, Induction of proliferation by IL-4 polarized macrophages ± grass allergen extract. Three macrophage/lymphocytes ratios are shown
(mean ± SEM, n = 8). B, Levels of cytokines/chemokines in supernatants of co-cultures (n = 6). Bars indicate mean values. Data were analyzed with
one way ANOVA. *P < .05, ** P < .01, and *** P < .001.
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unchanged compared to medium control macrophages
(data not shown).
M2 polarization of human AMΦ after endobronchial
allergen challenge
Next, we investigated the extent of macrophage po-
larization after endobronchial allergen challenge in healthy
and asthmatic subjects (Table 1). The inflammatory re-
sponse in the control and allergen challenged segments was
assessed by cell differentiation and cytokine measurementsTable 1 Patient characteristics
Healthy Asthmatic
No. 4 11
Sex (male/female) 4/0 9/2
Age (y) 45(40–50) 43(37-50)
Atopy no yes
FEV1 (% predicted) 108.3(103.8-11.2) 94(83.1-110.7)
FEV1/FVC ratio 79.6(75.1-80.3) 76.2(70.8-86.7)
Metacholine PC20 n.d. 1.5(0.9-5.7)
Allergen (BU/ml) 100 62.5(62.5-125)
IgE (U/ml) 23(9.5-68) 173(97–262)
Median and interquartile ranges (IQR) are given.of the recovered BAL fluid. The two segments that received
the standard allergen dose were similar with respect to the
influx of eosinophils (Table 2). A lower percentage of eosin-
ophils was found in the segment that received 1/10 of the
standard allergen dose (P < .01). Compared to baseline,
levels of IL-5 in BAL increased after allergen provocation
(P < .001), however with no significant differences between
the allergen doses (Additional file 1: Figure S1). For further
analysis, cells and supernatants from the two standard aller-
gen segments were pooled. On protein level, CCL17 and
CCL22 were found to be increased due to endobronchial
allergen challenge with differences between allergen doses
(Additional file 1: Figure S1) (P < .01).
The protein expression of CD86 measured by flow cy-
tometry was significantly higher in macrophages from
asthmatic patients compared to healthy subjects and
further up-regulated after standard allergen provocation
in asthmatic patients (P < .05) (Figure 4, A). The MFI
value of surface HLA-DR was higher in asthmatic patients
compared to non-asthmatic subjects but did not reach
statistical significance. No differences were observed for
the surface expression of CD206 (Figure 4, A).
Compared to isolated macrophages from the saline
segment, the mRNA expression of CCL13, CCL17, and
CLEC10A (normalized to individual baseline expression)
was increased after application of the standard allergen
Table 2 Bronchoalveolar lavage data
Segment Recovery (ml) Total cells (x 106) Macrophages (%) Eosinophils (%) Neutrophils (%) Lymphocytes (%) Epithelial cells (%)
B (H) 49 (35-58.8) 2.1 (1.5-3.6) 91 (88.3-92.9) 0 1 (0.6-1.8) 7.4 (4.5-9.8) 0.8 (0.5-1.8)
S (H) 73.5 (66.5-78) 7.7 (4.4-15.3) 88.9 (61.2-92) 0.3 (0-0.6) 2.4 (1.2-31) 5 (3.4-8.3) 0.7 (0.2-2.3)
A1/10 (H) 68.5 (64-78) 5.4 (5.3-6.2) 86.7 (76.1-93.4) 0.5 (0-1.6) 6.5 (1.6-12.5) 6.6 (2.5-10.3) 0.1(0-2.8)
A1 (H) 55.5 (47-61) 3.5 (2.7-5.5) 79.4 (73.7-86.3) 0.2 (0.4) 7.8 (3.3-11.3) 7.8 (3.3-10.4) 0.6 (0.3-1.1)
B (A) 52.0 (44-60) 4.7 (1.2-5.7) 91.3 (81-93.8) 0.3 (.0.5) 2 (0.3-2.3) 5.8 (3-12) 1 (0.8-2.5)
S (A) 55 (51-69) 5.6 (2.6-9.5) 88.3 (84.8-91) 0.3 (0-1.3) 3.8 (1.3-9.8) 5 (3.3-7.8) 0.8 (0.3-2)
A1/10 (A) 54 (47-63) 6 (3.9-14.2) 70.3 (29-84.5) 7.8 (3-30.3)***§ 3.5 (1.3-18.8) 3.8 (2-6.5) 1 (0.3-1.3)
A1 (A) 56 (48-63) 9.3 (3.9-20.9) 47.3 (31.3-63.8)***§# 30.8 (12.8-46)***§# 6.3 (1.8-9.3) 3.5 (2.5-4.8) 0 (0-0.7)
A2 (A) 43 (32-63) 8.1 (5-13.1) 38 (27.7-56.3)***§# 38.3 (10.3-63.8)***§# 6.5 (2.3-18)** 3.8 (2.3-6) 0.3 (0-9)
(H) Healthy subjects, and (A) asthmatic patients who underwent bronchoalveolar lavage at baseline (B) and 24 hours after instillation with saline (S), standard
allergen (A), in two different segments (A1 and A2), and one-tenth of the standard allergen dose (A1/10). Median and interquartile ranges (IQR) are given.
***versus baseline P < .001, **versus baseline P < .01, § versus saline P < .001, # versus A1/10 P < .01
Figure 4 Characterization of human alveolar macrophages (AMΦ) after endobronchial allergen provocation in healthy individuals and
asthmatics. AMΦ were isolated at baseline (B) and from saline (S), standard allergen (A) and one-tenth of the standard allergen dose (A1/10)
challenged segments. A, Protein surface marker expression of AMΦ, mean fluorescence intensities (MFI) after isotype control correction are shown
(n = 4 for healthy subjects and n = 6-8 for asthmatics). B, mRNA expression of CCL13, CCL17 and CLEC10A as fold induction compared to
individual baseline control (n = 7). C, Correlation between CCL17 and CLEC10A mRNA expression and eosinophilia in BAL of allergen challenged
segments (A + A1/10, n = 14). D, Gene expression under baseline conditions (as fold induction compared to mean baseline expression in
macrophages of healthy subjects) (n = 7). Data (A, and B) were analyzed with one way ANOVA. *P < .05, ** P < .01 **, and *** P < .001. The
Spearman rank correlation test was used in C.
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and CLEC10A but not CCL13 (P < .05) (Figure 4, B). In
contrast, the mRNA expression of CD206, CCL18, CCL23,
and the M1 marker CXCL10 were not changed by allergen
provocation (Additional file 2: Figure S2). In healthy
subjects no alteration of M2 marker mRNA expression
was observed in isolated macrophages in none of the
different segments (Additional file 3: Figure S3).
The mRNA expression of CCL17 and CLEC10A
(Figure 4, C) in macrophages isolated from the standard
allergen and low allergen segment correlated with the
percentage of eosinophils in BAL fluid (r = .76, P = .002
and r = .75, P = .002, respectively). As mRNA expression
of M2 markers in healthy subjects was not altered due
to allergen exposure, we normalized expression levels in
macrophages from asthmatic subjects relative to mean
baseline values of healthy subjects (= fold induction,
Figure 4, D and Additional file 2: Figure S2). This ana-
lysis showed an increased baseline expression of CCL13,
CCL17 and CLEC10A in macrophages from asthmatics
patients compared to healthy subjects.
Human AMΦ from endobronchial allergen challenged
lung segments are functionally altered
According to the in vitro model using human MDM and
autologous T-cells from peripheral blood, we evaluatedFigure 5 Induction of allergen-specific T-cell proliferation by human alv
in asthmatics. A, Proliferation of autologous CD4+ lymphocytes (T) after co-c
segments challenged with saline (S), one-tenth of the standard dose (A1/10) a
levels in the supernatant of co-cultures. Bars indicate mean values (n = 7), datathe induction of antigen-specific T-cell proliferation of
human AMΦ which were primed with allergen in vivo.
Alveolar macrophages were isolated from BAL fluid by
adherence and co-cultured with autologous T-cells from
peripheral blood.
Mean values of T-cell proliferation were higher with
macrophages isolated from the low dose and standard
allergen dose challenged segments, respectively com-
pared to the saline segment (P < .01, Figure 5, A). How-
ever, the overall magnitude of proliferation was about
10-fold lower when compared to the proliferation in-
duced by pulmonary myeloid dendritic cells of asthmatic
patients in a previous study. In this study dendritic cells
were isolated from BAL after endobronchial allergen
challenge by flow cytometry based cell sorting and co-
cultured likewise with autologous lymphocytes [16].
Cytokine and chemokine analysis of co-culture superna-
tants of either AMΦ or AMΦ + T-cells showed that
AMΦ isolated from asthmatics after endobronchial aller-
gen challenge released increased amounts of CCL17 and
CCL22 compared to AMΦ isolated from the saline chal-
lenged segment (P < .01, Figure 5, B). In addition in-
creased levels of CCL17 and CLL22 were also found in
BAL fluid from asthmatic patients after endobronchial
allergen challenge with both allergen doses (Additional
file 1: Figure S1).eolar macrophages (AMΦ) after endobronchial allergen provocation
ulture with AMΦ isolated from bronchoalveolar lavage from lung
nd the standard allergen dose (A), AMΦ/T-cell ratio 3:10. B, Chemokine
were analyzed by one way ANOVA. *P < .05, and **P < .01.
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induction of Th2 cytokines by CD4+ T-cells was observed.
Alveolar macrophages isolated from healthy subjects did
not induce any proliferation nor did they release CLL17 or
CLL22 (data not shown).
Discussion
This study provides evidence for an augmented expression
of CCL13, CCL17, and CLEC10A in AMΦ from patients
with mild asthma during episodes of acute allergic airway
inflammation. The expression of macrophage CCL17 and
CLEC10A was related to the degree of eosinophilic in-
flammation. As increased amounts of CCL17 have been
shown to attract CCR4+ effector cells like eosinophils or
specific Th2 lymphocyte subsets [17,18], it is tempting to
speculate that macrophages play an important role in
modulating the degree of allergic inflammation. Our data
is in line with and confirms recent results of Staples and
co-workers, who showed that human AMΦ from asth-
matic patients display a partial M2 polarization already
under non-inflamed conditions with increased mRNA
expression of CCL17, CLEC10A and protein release of
CLL17 and CCL22 [15].
It has been demonstrated in mouse models that macro-
phages undergo M2 polarization during the acute phase of
allergic airway inflammation. However, the time course of
polarization markers after resolution of the acute inflam-
mation has not been investigated. Our data demonstrate
that the up-regulated expression of established murine
M2 polarization markers (Ym1, Fizz1, and Arg) outlive
the inflammatory response. The decline of polarization
markers over time might be due to replacement by new
monocytes entering the alveolar space after resolution of
the cellular inflammation, which is also supported by the
concordant and continuous decline of all 3 investigated
M2 related genes. An impaired phagocytosis of E. coli by
murine M2 macrophages supports the hypothesis that
clearance mechanisms might be altered, making the air-
ways more susceptible for bacterial or viral infection
during this resolution period [19]. Therefore, polarized
macrophages seem to be capable to play a role in sus-
taining an inflammatory condition after acute allergen
exposure.
We found several markers of M2 polarization to be
induced in response to IL-4 in human MDM such as
CCL17 and CLEC10A. These polarized macrophages
induced allergen-specific T-cell proliferation and Th2
cytokine secretion. Importantly, IL-4 polarized human
MDM do not fully reflect the AMΦ phenotype in asth-
matics, as the cytokine milieu in vivo is not restricted to
solely M2 stimuli.
It was previously shown that IL-4 stimulation of murine
macrophages in vitro leads to increased CCL17 release
[18,20]. We could extend these findings for human AMΦderived from allergen challenged segments as these cells
express increased amounts of CCL17 on mRNA and pro-
tein level after allergen challenge. However, it remains to
be elucidated to which extent macrophages account for
the increased CCL17 levels in BAL of asthmatic patients
since dendritic cells and epithelial cells have also been
identified as prominent sources [21-24]. We did not ob-
serve CCL17 release by native T-cells of asthmatic patients
in our co-cultures [25]. In opposite to findings of Staples,
we found CCL17 mRNA already increased at baseline in
macrophages from mild asthmatic patients compared to
healthy subjects and additionally identified CCL13 to be
up-regulated. CCL13 is a potent chemokine which attracts
CCR3+ cells like eosinophils, Th2-lymphocytes, basophils
and correlates with asthma exacerbation [26,27]. CCL13
protein has been shown to be increased in BAL of asth-
matic patients compared to healthy controls [28]. Our
mRNA results in AMΦ show that polarized macrophages
represent an additional source of this protein beside
epithelial cells in response to allergen provocation in
the airways.
The macrophage galactose-type C-type lectin (MGL)
CLEC10A which we and others found up-regulated on
alveolar macrophages from asthmatic patients [15] recog-
nizes carbohydrate structures with terminal galactose or
N-acetylgalactosamine residues, which are present on nat-
urally occurring allergens [12,29]. Additionally, the man-
nose receptor (CD206) [30] and IgG receptor (CD32) [31]
are described to be increased on macrophages from asth-
matic patients. Whether this up-regulation is capable to
alter phagocytosis of M2 macrophages remains to be elu-
cidated. Interestingly, phagocytosis of bacteria is impaired
in patients with severe asthma [32,33] and IgG-opsonized
yeast are less effectively cleared by macrophages from
asthmatic patients [34]. Impaired phagocytosis of bacteria
was also reported from various in vitro models of M2
polarization, also supporting the hypothesis that pulmon-
ary clearance of inhaled pathogens might be hampered
[35]. In our study, CD206 was not differentially expressed
on macrophages from asthmatic patients compared to
healthy subjects and not regulated in response to allergen
exposure.
In asthmatic patients chitinases (chitotriosidase, CHIT1)
and chitinase-like proteins (YKL-40) in serum and BAL
correlate with the severity of the disease, the degree of
airway remodeling, and the frequency of asthma exacer-
bations [36-38]. These molecules are released from acti-
vated monocytes and macrophages and are suggested to
be linked with remodeling processes [39,40]. CCL18, a
macrophage-derived chemokine has been described to
attract T-lymphocytes and to promote collagen produc-
tion by human fibroblasts [41,42]. Interestingly, we did
not observe CCL18 up-regulation in alveolar macro-
phages 24 h after segmental allergen challenge, while we
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IL-4 stimulation. This is in line with a recent in vitro
study investigating the kinetics of CCL18 induction
showing maximum release at 72 h but no significant
change at 24 h after stimulation with allergen [41]. In
line with older reports, we found an increased expression
of HLA-DR and other co-stimulatory surface markers on
M2 macrophages [31,43]. Although the results from our
in vitro allergy model show that M2 macrophages induce
T-cell proliferation and the release of Th2 cytokines, we
were not able to confirm the magnitude of proliferation
and cytokine release in similar experiments using AMΦ.
Consequently, this questions their relevance for aller-
gen presentation. As a limitation, we did not investigate
whether macrophages from asthmatic patients exhibit a
suppressive function on DC-induced T-lymphocyte pro-
liferation as has been reported before [44].
There is increasing evidence that the different models
available to study the concept of macrophage polarization
are providing controversial results. Murine models of
allergic asthma revealed that the course of the allergic
airway inflammation was not influenced by the presence
or absence of IL-4 receptor-α bearing macrophages
which become polarized during the allergic inflammation
[45]. In contrast, the transfer of IL-4 receptor-bearing
macrophages aggravated the eosinophilic inflammation
in IL-4 receptor-deficient mice [46]. However, in an ani-
mal model of acute exacerbation M2 macrophages trig-
gered Th2 cytokines in CD4+ T-lymphocytes through
the interaction with CD80/CD86, which was not seen in
a model of mild chronic asthma [47]. A rhinovirus-
induced exacerbation study identified M2 macrophages
after allergen challenge which subsequently released more
Th2 cytokines and CCL11 after additional rhinovirus
infection. On the other side, depletion of macrophages
before allergen/rhinovirus challenge lead to reduced
eosinophilia, CCL11 and IL-13 levels [48]. Thus, func-
tional consequences of macrophage polarization might
become more apparent during asthma exacerbation
phases.
Conclusions
The main focus of our study was the role of macrophage
polarization in asthmatic patients. Taken together, we
were able to show a close relationship between the degree
of eosinophilic inflammation and M2 polarization, which
is characterized by an increased expression of CCL13,
CCL17 and CLEC10A. Together with the data from the
animal and in-vitro models these data indicate that M2
macrophages might contribute to the acute inflammation
by their Th2 cytokine and chemokine release. Future stud-
ies need to refine functional implications of M2 polarized
macrophages in particular with pathogen-induced exacer-
bations and with different asthma phenotypes.Methods
Kinetics of M2 marker expression in a mouse model of
acute asthma
Female BALB/c mice of 6–8 weeks of age were sensitized
according to the standard acute ovalbumin (ova)-model as
described before [49]. Mice were killed 24 h, 1 week, 2
weeks and 3 weeks after the last ova-aerosol challenge
(see methods section in the supplement). Alveolar mac-
rophages (AMΦ) were isolated from BAL by adherence
to plastic for 1 h at 37°C and 5% CO2. Interstitial mac-
rophages (IMΦ) were isolated from lung digests by anti-
CD11b magnetic bead separation (Miltenyi Biotech,
Bergisch Gladbach, Germany) and subsequent plastic ad-
herence to remove contaminating cells. Real time PCR of
M2 marker gene expression and cytokine measurement in
BAL was performed as described below.
Clinical study design and study population
Peripheral blood derived mononuclear cells (PBMC) and
autologous lymphocytes were obtained from eight atopic
subjects who were allergic to grass. For isolation of AMΦ,
eleven patients with mild intermittent asthma and four
healthy controls underwent endobronchial allergen provo-
cation with grass allergen extract (SQ225, Alk-Albello
Arzneimittel GmbH, Hamburg, Germany) as described in
detail before (see the methods section in the supplement)
[50,51]. For isolation of CD4+ lymphocytes peripheral
blood was taken one day before endobronchial allergen
challenge. The clinical study was performed in compliance
with the Declaration of Helsinki. The Ethics committee of
Hannover Medical School approved the study (ref. #5670).
All study subjects gave written consent after being fully
informed about the purpose of study and the potential
risks that were associated with the study procedures.
Characterization of in vitro polarized human monocyte
derived macrophages
Isolation of monocytes and lymphocytes from peripheral
blood of atopic individuals was performed as described
before [52]. Briefly, PBMC were isolated from whole
blood by density gradient centrifugation using Ficoll-
Paque PLUS (GE Healthcare Europe, Freiburg, Germany).
Monocytes were isolated with anti-CD14 antibodies
(Miltenyi Biotech, Bergisch Gladbach, Germany) by mag-
netic cell separation of PBMC and cultured for 6 days in
RPMI 1640 + Glutamax (supplemented with 7% of autolo-
gous serum and 800 U/ml GM-CSF). GM-CSF was
chosen for differentiation as it leads to macrophages which
resemble more closely the alveolar phenotype [53]. Cells
negative for CD14 were collected as lymphocytes and
kept frozen until co-culture at −80°C. After differentiation
to macrophages cells were alternatively activated with
10 ng/ml IL-4 for 24 h and afterwards stimulated with
2000 BU/ml grass allergen extract (SQ225, Alk-Albello
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Cells were harvested and splitted for either analysis of
surface markers or M2 marker gene expression or fur-
ther co-cultured with autologous lymphocytes.Isolation of human alveolar macrophages after
endobronchial allergen challenge
Cells from BAL were re-suspended in culture medium
with 7% autologous serum. Macrophages were isolated by
plastic adherence for 1 h at 37°C and 5% CO2. Adherent
cells were washed 3 times with PBS and either transferred
to RLT-buffer (Qiagen, Hilden, Germany) for RT-PCR
analysis or co-cultured with autologous lymphocytes.Co-culture of human macrophages and autologous CD4+
lymphocytes
Both, monocyte-derived macrophages and AMΦ were
co-cultured with autologous lymphocytes in three or
two ratios, respectively (0.3:10, 1:10 and 3:10). In detail,
0.3-3 × 104 macrophages were cultured per well with 1 ×
105 lymphocytes in triplicates. Proliferation was assessed
by 3H-thymidine incorporation after 5 days of culture as
described before [19]. For co-culture of AMΦ autologous
CD4+ lymphocytes were isolated by negative depletion
using Dynabeads (Invitrogen, Darmstadt, Germany) from
peripheral blood. An AMΦ/T-lymphocyte ratio of 1:10
and 3:10 was analyzed. For cytokine measurements, super-
natants from AMΦ that were cultured for 5 days in the
presence or absence of grass allergen extract (2000 BU/ml)
were analyzed.Analysis of M2 markers by RT-PCR
RNA was extracted either from MDM or from AMΦ
after plastic adherence using RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufactures instruc-
tions. RNA transcription was performed with an Omnis-
kript Reverse Transcription Kit (Roche, Basel, Switzerland).
Real time PCR was performed with LightCycler®FastStart
DNA MasterPlus Sybr Green 1 (Roche, Basel, Switzerland)
(see the methods section in the supplement). The expres-
sion of marker genes was normalized to a house keeping
gene (β-actin for mouse and GAPDH for human samples)
and quantified according to the ΔΔCt-method [54].Analysis of cytokines from supernatants of human MDM
or AMΦ, and BAL fluid
Release of cytokines to supernatants of in vitro cell
cultures was performed by Multiplex MAP cytokines/
chemokine panels (Merck Millipore, Billerica, USA).
Measurement of cytokines and chemokines in BAL
was performed using a Th1/Th2 10-plex from MSD
(Meso Scale Discovery, Rockville, USA).Statistics
Statistical analyses were performed using one way Anova
with Newman-Keuls post hoc testing. (GraphPad Prism
Version 4; GraphPad Software, San Diego, California). Data
were log-transformed if not normally distributed. Results
were considered to be significant at a P value of < 0.05.
Additional files
Additional file 1: Figure S1. Cytokines and chemokines in
bronchoalveolar lavage fluid (BAL) after segmental allergen provocation
in asthmatic patients. Patients underwent BAL at baseline (B) and
24 hours after instillation with saline (S), one-tenth of the standard dose
(A1/10) and standard allergen (A) in two different segments (A1 + A2).
Levels of IL-5, CCL17, and CCL22 are shown. BAL from both standard
allergen segments (A = A1 + A2) was pooled for CCL17 and CCL22
measurement. Bars indicate mean values (n = 11); data were analyzed by
one way ANOVA. *P < .05, **P < .01 and ***P < .001.
Additional file 2: Figure S2. Gene expression of M2 marker genes in
alveolar macrophages from asthmatic patients. Asthmatic patients
underwent bronchoalveolar lavage at baseline (B) and 24 h after
provocation with saline (S), standard allergen (A) and one-tenth of the
standard allergen dose (A1/10). RNA expression is shown as fold induction
compared to the mean baseline expression in healthy patients (n = 7).
Additional file 3: Figure S3. Gene expression of M2 marker genes in
alveolar macrophages from healthy patients. Healthy subjects underwent
bronchoalveolar lavage at baseline (B) and 24 h after provocation with
saline (S), standard allergen (A) and one-tenth of the standard allergen
dose (A1/10). RNA expression is shown as fold induction compared to
the individual baseline expression in healthy patients (n = 4).
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AF647: Alexa Fluor 647; AMΦ: alveolar macrophages; APC: Allophycocyanin;
Arg1: Arginase 1; BAL: Bronchoalveolar lavage; CLEC10A: Macrophage
galactose C-type lectin (CD301); cpm: Counts per minute; CXCL10: Interferon
gamma induced protein (IP10); DC: Dendritic cells; FACS: Fluorescence-
activated cell sorting; FIZZ1: Found in inflammatory zone; M1: Classically
activated (macrophages); IMΦ: Interstitial macrophages; i.p.: Intraperitoneal;
M2: Alternatively activated (macrophages); MDM: Monocyte-derived
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T-lymphocyte-derived eosinophil chemotactic factor (ECF-L).
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